
DAVITA INC
DVANYSETrading Snapshot
- Day Range
- $941.75 β $956.61
- 52-Week Range
- $101.00 β $247.49
- Volume
- $2.49B
- Avg Volume
- $2.15B
- Shares Outstanding
- 64.2M
- Next Earnings
- Sep 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $13.64B
- Last Q Revenue
- $3.55B
- P/E Ratio
- 13.7
- P/S Ratio
- 0.8x
- EPS (TTM)
- $12.21
- Dividend Yield
- β
Why Investors Own DVA
- βHigh-growth profile β revenue up +57.1% YoY with expanding US Equity exposure.
- βHealthy economics β 72% gross margin and 30% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About DAVITA INC
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
DAVITA INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift DVA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
DAVITA INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.